Recommendations: Combinations of fluoropyrimidines, either 5-FU or capecitabine, and oxaliplatin constitute the bases for stage III colon cancer adjuvant treatment [I, A; European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) v.1.1 score: B]....Patients with high-risk stage II colon cancer may be considered for 3 months of CAPOX, as the IDEA-pooled analysis showed non-inferiority of 3 months of CAPOX and inferiority of 3 months of FOLFOX when compared with 6 months of FOLFOX, with all the limitations of post-hoc analyses [II, B].

...the panel recommends chemotherapy corresponding to initial therapy for metastatic disease (eg, FOLFIRI, FOLFOX, or CAPEOX chemotherapy alone or with bevacizumab; FOLFIRI or FOLFOX with panitumumab or cetuximab; FOLFOXIRI alone or with bevacizumab)

The 3-year DFS rate was 88.2% in the 3-month arm and 87.9% in the 6-month arm (hazard ratio [HR], 1.12; 95% CI, 0.67–1.87). With CAPOX, the 3-year DFS rate was 88.2% in the 3-month arm and 88.4% in the 6-month arm (HR, 1.13; 95% CI, 0.65–1.96). The discontinuation rate in the 3- and 6-month arms was 10% and 31% for mFOLFOX6 ( P = 0.0193), and 15% and 35% for CAPOX ( P < 0.0001), respectively. The incidence of grade ≥2 PSN was significantly lower in the 3-month arm than in the 6-month arm (16% and 43%, respectively, P < 0.0001).